Revvity (RVTY) 2025 Conference Summary Company Overview - **Company**: Revvity (RVTY) - **Date**: May 13, 2025 - **Industry**: Life Sciences Tools and Diagnostics Key Points 1. Q1 Performance and Guidance - The first quarter showed solid performance despite a different macro environment than initially assumed for 2025 guidance [4][5] - The diagnostics and software businesses performed exceptionally well, contributing to the overall strength of the portfolio [4][5] - The company maintained full-year guidance despite a weaker macro backdrop due to prudent initial guidance [5] 2. Tariff Impact and Mitigation Strategies - Gross tariff headwinds were estimated at $135 million, with a net impact of approximately $0.12 on EPS after operational mitigation [6][12] - The majority of tariff impacts are expected in the second quarter, with operational mitigation strategies being implemented [6][12] - The company has a dual manufacturing strategy to enhance supply chain resiliency, including a GMP facility in San Diego and another outside the US [10] 3. Academic and Government Market Exposure - Academic and government customers account for 12% of global revenue, with over 5% in the US [21] - There is cautiousness in these segments due to uncertainties around indirect expense reimbursements and NIH funding levels [22][24] 4. Pharma and Biotech Market Trends - The pharma and biotech sectors showed positive growth in Q1, but there is uncertainty due to macroeconomic factors and tariffs [28] - Instrumentation sales are expected to face continued pressure, particularly from mid and large-sized pharma customers [29][30] 5. Geographic Performance - China represents 16% of total revenue, with diagnostics showing high single-digit growth while life sciences experienced a slight decline [34] - The company anticipates continued choppiness in the China life sciences market but modest growth in diagnostics [34][35] 6. Software Business Strength - The software business is highlighted as a major area of strength, with new product launches and a focus on large molecule capabilities [48][49] - The company is expanding into new customer groups and markets, such as material science, which has shown good traction [49] 7. Margin Expectations and Cost Management - The company expects balanced margin expectations for the year, with temporary belt-tightening measures in place to mitigate tariff impacts [50][51] - There are no plans for additional structural cost reductions, but ongoing monitoring will occur [51] 8. Capital Allocation and M&A Strategy - Revvity has adopted a balanced approach to capital deployment, including share buybacks and selective M&A opportunities [55][56] - The company is cautious about M&A in the current market, noting that private companies are not in a rush to sell despite lower valuations [57][59] 9. Underappreciated Aspects of Revvity - The company’s differentiated portfolio and execution capabilities are not fully recognized in the market [61][62] - There is potential for margin expansion that has yet to be demonstrated due to current market pressures [62][63] 10. Future Outlook - The company remains optimistic about its long-term growth potential, particularly in the reagents business and software capabilities [41][48] - Continued execution and clarity in macroeconomic conditions are essential for demonstrating the company's margin expansion opportunities [63] This summary encapsulates the key insights and data points from the Revvity conference, providing a comprehensive overview of the company's current performance, challenges, and strategic outlook.

来源：弈赫市场咨询 这份砖石工具市场分析报告的受众群体广泛，主要包括行业投资者、市场营销人员、产品开发者以及政策制定者等。对于投资者而言，了解市场趋势和竞争 对手的动态可以帮助其做出更为明智的投资决策；而市场营销人员则可以通过分析报告中的消费数据和趋势，优化营销策略，增强市场竞争力。此外，产品 开发者亦可通过该报告获得行业内的最新技术和创新动向，进而提升产品研发的针对性与市场接受度。政策制定者则可以借助这份报告深入了解行业发展现 状及未来潜力，为相关政策的制定与调整提供数据支持。综合而言，这份报告是对砖石工具市场进行全面深入理解的极佳工具。 在砖石工具市场中，主要参与者包括多家知名企业和一些新兴的市场竞争者。这些公司在行业内具有较高的市场份额，以技术创新、产品质量和客户服务著 称。市场领军企业如德威、博世、3M和山特等，凭借着强大的研发能力和广泛的市场网络，已经稳固了自己的市场地位。同时，市场中也涌现了许多中小 型企业，它们通过创新的产品以及灵活的市场策略，寻求在市场中占有一席之地。这种多样化的市场结构使得砖石工具市场竞争尤为激烈，促使行业不断向 前发展。 北京弈赫国际信息咨询有限公司是一家业务覆盖全球的利基 ...

[Table_StockAndRank] 巨星科技(002444) 证券研究报告 公司研究 [Table_ReportType] 公司点评报告 | | 买入 | | --- | --- | | 投资评级 | | | | | 中美贸易摩擦缓和，关税水平大幅降低。此次中美经贸会谈双方达成共识互 相降低关税水平，从前期的 125%大幅下降至 34%，其中 10%继续执行、 24%则给予 90 天暂缓期，并且不排除进一步下调的可能。对于工具板块而 言，目前中国对美出口税率水平回落至79%（其中包括301关税25%、IEEPA 关税 54%），并且在 90 天暂缓期内实际税率约为 55%。根据我们测算，终 端零售价同比上调接近 20%即可保障原有产业链利润空间。当前北美市场 有公司工具产品已开始涨价，中国产能经济性有望修复。 积极推进产能转移，全球布局应对冲击。公司对美出口主要风险敞口约 10 亿美元，其中中国 6 亿美元（3 亿美元 ODM+3 亿美元 OBM）、越南 4 亿美 元（均为 ODM），分别面临 79%、46%的关税，在暂缓期内分别为 55%、 10%。一方面考虑到税率差距，公司自 4 月起已加速建设位于 ...

[Table_StockAndRank] 巨星科技(002444) | | 买入 | | --- | --- | | 投资评级 | | | | | [Table_Author] 姜文镪 新消费行业首席分析师 执业编号：S1500524120004 邮 箱：jiangwenqiang@cindasc.com 龚轶之 新消费行业分析师 执业编号：S1500525030005 邮 箱：gongyizhi@cindasc.com 王锐 机械行业首席分析师 执业编号：S1500523080006 邮 箱：wangrui@cindasc.com 信达证券股份有限公司 CINDA SECURITIES CO.,LTD 北京市西城区宣武门西大街甲127号金隅大厦B 座 邮编：100031 [Table_Title] 巨星科技：关税摩擦缓和，对美业务有望修复 证券研究报告 公司研究 [Table_ReportType] 公司点评报告 | [Table_Profit 重要财务指标 ] | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | ...

中国企业通过首轮贸易摩擦的历练已积累了一定应对经验，正以更加主动的姿态化解新一 轮关税政策带来的冲击。 文：国金宏观宋雪涛/厉梦颖 近期，全球贸易紧张局势似乎暂时得到了缓解。在"对等关税"暂缓90天期间，特朗普政府一直积极在 与印度、日本、韩国、英国等国家积极开展贸易谈判。其中，美英贸易谈判在本轮磋商中进展最为迅 速，英国率先达成协议。5月8日，特朗普政府于华盛顿正式公布了英美贸易协定框架文本。 中美两国在瑞士举行贸易谈判后，共同发布了《中美日内瓦经贸会谈联合声明》。根据声明内容，美国 将保留对华商品10%的对等关税，同时暂停实施另外24%关税，暂停期限为90天。自特朗普政府上任 以来，加上 20%的芬太尼关税，美国已 累计对中国商品加征了30%的关税。 然而，在贸易协定正式达成之前，仍存在诸多不确定性。在这种高度不确定的贸易环境下，中美两国的 上市公司是如何看待关税问题？ 一、中美上市公司财报的含"税"量 截至5月5日，共有5516家A股上市公司发布了2025年第一季度报告，其中41家公司在报告中提及"关 税"一词。这些公司主要集中在 机械设备（通用设备为主）、医药生物（医疗器械为主）、汽车（汽车 零部件为 ...

Financial Data and Key Metrics Changes - The company reported $47 million in revenue for Q1 2025, exceeding expectations and showing a growth of over $4 million from Q4 2024 [6][27] - GAAP net loss before noncontrolling interests was $53 million for Q1 2025, compared to a loss of $23 million in Q1 2024 [27] - Adjusted EBITDA was negative $11 million for Q1 2025, down from a positive $8 million in Q1 2024 [28] - Basic and diluted EPS for Q1 was a loss of $0.21 per share, compared to a loss of $0.09 per share in Q1 2024 [30] Business Line Data and Key Metrics Changes - The Nucleic Acid Production (NAP) segment generated $29 million in revenue for Q1 2025, an increase of $1 million from Q4 2024 [6] - The Biologics Safety Testing (BST) segment reported $18 million in revenue for Q1 2025, up $3 million from Q4 2024 and flat compared to Q1 2024 [6][35] - The adjusted EBITDA margin for the BST segment was 70%, indicating strong performance [35] Market Data and Key Metrics Changes - Revenue by customer type in Q1 was 29% from biopharma, 28% from life science and diagnostics, 6% from academia, 7% from CDMO, and 30% through distributors [7] - Revenue by geography was 62% from North America, 15% from EMEA, 15% from Asia Pacific, and 8% from China [7] Company Strategy and Development Direction - The company is focused on a return to growth strategy and building a diversified franchise as a life science tool provider and clinical partner [10] - The strategy includes vertical integration in the NAP segment to enhance quality, speed, and cost efficiency [8] - The company aims to expand its product and service portfolio to drive long-term sustainable growth [10] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges of transitioning from a COVID-driven revenue model to a more diversified business [39] - The company is closely monitoring trade dynamics and working to mitigate potential impacts from tariffs [39] - The cash position of $285 million is seen as sufficient to manage the reset period while focusing on long-term growth [40] Other Important Information - The company plans to publish its 2024 sustainability report, highlighting its commitment to sustainability and long-term strategic objectives [25] - The integration of recent acquisitions is progressing well, enhancing operational capabilities and supply chain control [32] Q&A Session Summary Question: Focus areas for new trials and reasons for discontinuation - Management noted that while preclinical programs were flat, clinical programs showed growth, indicating a focus on later-stage projects due to funding conservatism [44][46] Question: Drivers of incremental demand in the next 12-18 months - Incremental demand is expected from clinical progression, new business wins, and the transition from bulk reagent supply to comprehensive service offerings [48] Question: Opportunities for market share due to U.S. manufacturing - The company sees potential for market share growth as interest in U.S.-based manufacturing increases, particularly in the mRNA space [51][54] Question: Impact of U.S. policy changes on customer buying patterns - Customers are experiencing mixed impacts from government funding changes, with some securing long-term funding while others delay decisions [60] Question: Government work and exposure - The company has no direct government work currently, with past contracts fulfilled, but remains open to future opportunities [66] Question: Seasonality in BST revenue - Q1 is typically a high point for BST revenue, influenced by manufacturing cycles and strong performance in China [70][72]

出口链系列 02：关税调整影响及企业近况解读 20250512 摘要 • 春风动力四轮车美国市场销售贡献显著，约占总收入 20%，毛利贡献达 30%，但面临关税调整风险。公司通过突击出口、准备库存和增加墨西哥 产能等措施积极应对关税变化，以确保供应链稳定和市场份额。 • 捷昌驱动对美敞口主要集中在线性驱动产品，受关税直接影响的营收占比 不到 10%。公司通过海外产能布局（马来西亚和美国工厂）和与客户协商 提价等方式，有效抵御了关税波动，降低了负面影响。 • 捷昌驱动的估值核心驱动因素在于人形机器人业务，特别是线性执行器和 灵巧手电机模组。关税问题缓解后，人形机器人业务进展可能使其估值更 具优势，存在较大的提升空间。 • 浙江鼎力作为高空作业平台龙头企业，前期受中美关税影响较大，目前股 价虽有所回升，但仍低于关税事件前水平。公司主要产能位于国内，暂无 海外建厂计划，通过加紧对美发货应对关税。 • 五金工具行业是机械板块中对美敞口最高的行业，中国企业在全球市场中 扮演代工厂角色。关税政策变化导致产能向东南亚转移，龙头企业有望通 过海外产能转移抢占市场份额。 Q&A 中美关税缓和对机械行业出口企业的影响如何？ 中美 ...

交出一份亏损的年度"成绩单"后，三超新材（300554）在近日举行的业绩说明会上称，公司在光伏领域 的业务规划有部分调整，"但公司认为，光伏行业仍然前景可期，公司在金刚线的技术研发创新方面， 将继续投入，保持技术的领先性"。 三超新材及子公司主要从事超硬材料工具和半导体制造相关设备的研发、生产和销售。2024年度，公司 营收主要来自电镀金刚线和金刚石砂轮，金刚石砂轮中的半导体耗材营收较上年有较大增长，半导体设 备首次实现营收，但占比较小。由于光伏行业的剧烈波动，硅切片线单价和销量均大幅下滑，公司的营 业收入较上年下降明显。 针对未来行业发展趋势，三超新材强调，公司判断光伏行业仍是极具前景的行业，但金刚线行业竞争加 剧，产品价格及毛利率逐年下降；硅切片金刚线细线化接近碳钢线物理极限，钨丝正逐渐成为基材，公 司在具体产品方面，会进行策略性调整，但会坚持研发，保持技术的领先性；半导体行业用相关产品 (耗材及装备)，进口替代空间很大，是公司的重点发展方向。 三超新材表示，未来公司仍将秉持立足国内、积极开拓海外市场的策略，会积极利用各方市场资源，重 视和拓展海外市场，尤其是部分性价比具备竞争优势的相关产品，要争取逐步走 ...

证券代码：300554 证券简称：三超新材 南京三超新材料股份有限公司投资者关系活动记录表 编号：2025-01 | | ☐特定对象调研 ☐分析师会议 ☐媒体采访 业绩说明会 | | --- | --- | | 投资者关系活动类别 | ☐新闻发布会 ☐路演活动 | | | ☐现场参观 | | | ☐其他（请文字说明其他活动内容） | | 参与单位名称及人员姓 | 线上参与公司2024年度网上业绩说明会的投资者 | | 名 | | | 时间 | 2025年05月09日 15:00-17:00 | | 地点 | 价值在线（https://www.ir-online.cn/）网络互动 | | 上市公司接待人员姓名 | 董事长、总经理：邹余耀 | | | 董事、董事会秘书：吉国胜 | | | 董事、财务总监：姬昆 | | | 独立董事：余刚 | | | 保荐代表人：傅鹏翔 | | | 1.请问公司或公司参股公司有产品应用于外骨骼机器人嘛？ | | | 答：您好！公司暂未有产品直接应用于外骨骼机器人方面。谢谢！ | | 投资者关系活动主要 | 2.公司产品可以用于AI芯片领域嘛？公司CMP-DISK产品可以用 | | ...

丨证券研究报告丨 行业研究丨专题报告丨机械 [Table_Title] 从海外龙头财报看美国关税影响 报告要点 [Table_Summary] 整体来看，面对全球对等关税，海外龙头主要通过前期备货、供应链调整、价格转嫁、内部降 本控费等多种方式，来尽量降低影响。价格方面，虽然目前不同公司有所分化，如史丹利百得 已进行价格上涨并且预计 Q3 继续上涨，而亚马逊、高机龙头、Rational 等目前虽尚未涨价， 但后续预计仍需要在一定程度上向美国终端消费者涨价以减缓成本上升的压力。库存方面，各 家基本都已在关税生效前进行了库存储备，以应对关税上涨带来的成本压力。 分析师及联系人 [Table_Author] 赵智勇 曹小敏 SAC：S0490517110001 SAC：S0490521050001 SFC：BRP550 请阅读最后评级说明和重要声明 %% %% %% %% research.95579.com 1 机械 cjzqdt11111 [Table_Title2] 从海外龙头财报看美国关税影响 [Table_Summary2] 引言：从海外龙头财报看美国关税影响 面对美国对等关税，海外公司也受到不同程度的成 ...